Recro Pharma Inc (NASDAQ:REPH) Expected to Post Earnings of -$0.36 Per Share

Wall Street brokerages expect that Recro Pharma Inc (NASDAQ:REPH) will report earnings per share of ($0.36) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Recro Pharma’s earnings. The highest EPS estimate is ($0.04) and the lowest is ($0.83). Recro Pharma reported earnings of ($0.62) per share in the same quarter last year, which would indicate a positive year over year growth rate of 41.9%. The firm is scheduled to announce its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Recro Pharma will report full-year earnings of ($0.54) per share for the current fiscal year, with EPS estimates ranging from ($1.90) to $0.12. For the next year, analysts anticipate that the firm will post earnings of $0.06 per share, with EPS estimates ranging from ($1.56) to $0.76. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that cover Recro Pharma.

Recro Pharma (NASDAQ:REPH) last announced its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.69. Recro Pharma had a negative net margin of 83.56% and a negative return on equity of 472.52%. The business had revenue of $25.07 million during the quarter, compared to analysts’ expectations of $20.51 million.

A number of brokerages have commented on REPH. Zacks Investment Research cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, June 19th. ValuEngine cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Monday, May 13th. Roth Capital reaffirmed a “neutral” rating and set a $7.50 target price (down from $15.00) on shares of Recro Pharma in a report on Monday, March 25th. Finally, Oppenheimer upped their target price on shares of Recro Pharma from $9.00 to $15.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $10.95.

REPH stock traded up $0.53 during midday trading on Friday, reaching $10.17. 712,611 shares of the company’s stock traded hands, compared to its average volume of 222,623. Recro Pharma has a 52-week low of $4.78 and a 52-week high of $10.32. The company has a market cap of $213.83 million, a PE ratio of -4.08 and a beta of -0.18. The company has a current ratio of 3.56, a quick ratio of 3.18 and a debt-to-equity ratio of 4.04. The stock’s 50-day moving average is $9.39.

In other news, CEO Geraldine Henwood sold 144,806 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $8.89, for a total value of $1,287,325.34. Following the completion of the sale, the chief executive officer now directly owns 342,947 shares of the company’s stock, valued at $3,048,798.83. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Arnaud Ajdler acquired 40,000 shares of Recro Pharma stock in a transaction dated Friday, May 17th. The stock was purchased at an average cost of $9.00 per share, with a total value of $360,000.00. The disclosure for this purchase can be found here. Corporate insiders own 20.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers increased its position in Recro Pharma by 47.8% during the fourth quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock worth $169,000 after buying an additional 7,679 shares during the last quarter. BlackRock Inc. increased its position in Recro Pharma by 5.7% during the fourth quarter. BlackRock Inc. now owns 1,154,815 shares of the specialty pharmaceutical company’s stock worth $8,199,000 after buying an additional 62,787 shares during the last quarter. Bank of New York Mellon Corp increased its position in Recro Pharma by 18.8% during the fourth quarter. Bank of New York Mellon Corp now owns 57,679 shares of the specialty pharmaceutical company’s stock worth $410,000 after buying an additional 9,118 shares during the last quarter. Geode Capital Management LLC increased its position in Recro Pharma by 12.3% during the fourth quarter. Geode Capital Management LLC now owns 157,953 shares of the specialty pharmaceutical company’s stock worth $1,121,000 after buying an additional 17,299 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Recro Pharma by 210.4% during the fourth quarter. Bank of America Corp DE now owns 27,182 shares of the specialty pharmaceutical company’s stock worth $193,000 after buying an additional 18,424 shares during the last quarter. 56.99% of the stock is owned by hedge funds and other institutional investors.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Recommended Story: Net Margin

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.